Hypertensive disease
|
0.550 |
Biomarker
|
group |
BEFREE |
This is consistent with dysregulated (RGS5-mediated) AT<sub>1</sub>R signaling that could contribute to excessive vasoconstriction in hypertension.
|
29061726 |
2017 |
Hypertensive disease
|
0.550 |
Biomarker
|
group |
BEFREE |
Multiple SNPs in combination in RGS5 may confer risk for hypertension.
|
19863299 |
2009 |
Hypertensive disease
|
0.550 |
AlteredExpression
|
group |
BEFREE |
Here, we investigated the influence of regulator of G protein signaling 5 (RGS5), an inhibitor of Gα<sub>q/11</sub> and Gα<sub>i/o</sub> activity, on blood pressure and the VSMC phenotype during experimental hypertension.
|
29208700 |
2018 |
Hypertensive disease
|
0.550 |
GeneticVariation
|
group |
BEFREE |
In this study, we investigated the association between RGS5 gene variants and hypertension in the Mongolian and Han populations.
|
26782409 |
2015 |
Hypertensive disease
|
0.550 |
GeneticVariation
|
group |
BEFREE |
The strongest signal for hypertension was for rs2815272 in the RGS5 gene (P = 9.3 × 10).
|
21881522 |
2011 |
Essential Hypertension
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Thus, we assessed the relationship between RGS5 genetic polymorphisms and essential hypertension (EH) in Chinese.
|
19863299 |
2009 |
Essential Hypertension
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Association of regulator of G protein signaling (RGS5) gene variants and essential hypertension in Mongolian and Han populations.
|
26782409 |
2015 |
Schizophrenia
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
RGS2 and RGS5 genotypes predicted severity of baseline symptoms in schizophrenia.
|
18262772 |
2008 |
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Similarly, RGS-5 is overexpressed in highly angiogenic astrocytomas but not in hypoxia-inducible factor-1alpha (HIF-1alpha)-deficient tumors, which grow along preexisting brain capillaries without inducing neovessels.
|
15459006 |
2005 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
One family member, RGS5, has recently been identified as a key regulator of vascular remodeling and pericyte maturation in tumors.
|
19467451 |
2009 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We found high-frequency expression of MAGE-A9 and NY-ESO-1 in 36% and 55% of samples, respectively, and overexpression of PRAME, RAGE-1, CA-IX, Cyclin D1, ADFP, C-MET, and RGS-5 in many of the tumor samples.
|
24777966 |
2013 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
RGS5 expression by the cancer vasculature triggered and retained by the proangiogenic microenvironment supports its exploitation as a novel biomarker and opens the path to explore new possibilities of therapeutic intervention aimed at targeting tumor blood vessels.
|
22130514 |
2012 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Immunohistochemical staining using serial sections for endothelial cell markers (CD31 and CD34) and smooth muscle cell markers (alpha-SMA and desmin), as well as fluorescence double staining, strongly suggested that tumour endothelial cells were the main location of RGS5 in RCC.
|
15095478 |
2004 |
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Twenty-six genes, including TFF3, DACH1, RGS5, and GHR, were shown to exhibit altered expression in tumors from patients with recurrence versus non-recurrent (fold change ≥1.5, p < 0.05), and the gene expression alterations were confirmed using qRT-PCR.
|
26585578 |
2015 |
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our results indicated that RGS5 may be a potential target for cancer therapy.
|
25891540 |
2015 |
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The regulator of G-protein signaling 5 (RGS5) has been reported to be highly expressed in some malignant tumors.
|
23868206 |
2013 |
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The present study focused on 3 upregulated molecules, integrin β3 (ITGB3), secreted phosphoprotein 1 (SPP1) and regulator of G-protein signaling 5 (RGS5), and 2 molecules that were downregulated in PVI tissue compared with cancer tissue, metallothionein 1G (MT1G) and metallothionein 1H (MT1H), as determined by cDNA microarray analysis.
|
29434872 |
2018 |
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
RGS5 expression by the cancer vasculature triggered and retained by the proangiogenic microenvironment supports its exploitation as a novel biomarker and opens the path to explore new possibilities of therapeutic intervention aimed at targeting tumor blood vessels.
|
22130514 |
2012 |
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The aim of the present study was to investigate the expression of RGS5 in EOC, as well as its association with cancer differentiation, metastasis and clinicopathological parameters.
|
30365142 |
2019 |
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The most immunogenic TAAs for HCC are survivin, CCND1, and RGS5.
|
28330473 |
2017 |
Liver carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that over-expression of RGS5 promotes tumor metastasis by inducing epithelial-mesenchymal transition in HCC.
|
23868206 |
2013 |
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Studies conducted to localize the protein products of these genes by immunohistochemical staining of tissue arrays with up to 350 cores of tissues, and by in situ hybridization led to the discovery of novel sinusoidal endothelial cell markers in hepatocellular carcinoma: podocalyxin-like and regulator of G protein signaling-5.
|
15154008 |
2004 |
Liver carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Nuclear grade, RGS5 expression, and EpCAM expression were significantly higher in the PD-L1-positive HCC group compared with the PD-L1-negative HCC group (P<0.05).
|
31423211 |
2019 |
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical staining for RGS5 in 60 HCC cases demonstrated that RGS5 protein levels were higher in cancerous tissue compared with paired noncancerous tissue in 63.3% of HCC cases.
|
29434872 |
2018 |
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
The aim of the present study was to investigate the expression of RGS5 in EOC, as well as its association with cancer differentiation, metastasis and clinicopathological parameters.
|
30365142 |
2019 |